{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T11:50:23Z","timestamp":1783770623489,"version":"3.55.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,26]],"date-time":"2024-05-26T00:00:00Z","timestamp":1716681600000},"content-version":"am","delay-in-days":330,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejpn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Paediatric Neurology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.ejpn.2023.05.001","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T17:45:18Z","timestamp":1683827118000},"page":"22-28","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Treatments of paediatric multiple sclerosis: Efficacy and tolerance in a longitudinal follow-up study"],"prefix":"10.1016","volume":"45","author":[{"given":"Anne-Charlotte","family":"Saponaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1847-7504","authenticated-orcid":false,"given":"Thomas","family":"Tully","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Maillart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Maurey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8409-2365","authenticated-orcid":false,"given":"Kumaran","family":"Deiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1\u20132","key":"10.1016\/j.ejpn.2023.05.001_bib1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.neurol.2019.02.002","article-title":"Paediatric onset multiple sclerosis","volume":"176","author":"Deiva","year":"2020","journal-title":"Rev. Neurol. (Paris)"},{"issue":"9 Suppl 2","key":"10.1016\/j.ejpn.2023.05.001_bib2","first-page":"S97","article-title":"Pediatric multiple sclerosis: conventional first-line treatment and general management","volume":"87","author":"Ghezzi","year":"2016","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.ejpn.2023.05.001_bib3","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1056\/NEJMoa1800149","article-title":"Trial of fingolimod versus interferon beta-1a in paediatric multiple sclerosis","volume":"379","author":"Chitnis","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ejpn.2023.05.001_bib4","article-title":"Increased relapse rate in paediatric-onset compared with adult-onset multiple sclerosis","volume":"66","author":"Gorman","year":"2009","journal-title":"Arch Neurol [Internet]"},{"issue":"8","key":"10.1016\/j.ejpn.2023.05.001_bib5","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/archneurol.2009.135","article-title":"Difference in disease burden and activity in paediatric patients on brain magnetic resonance imaging at time of multiple sclerosis onset vs adults","volume":"66","author":"Waubant","year":"2009","journal-title":"Arch. Neurol."},{"issue":"23","key":"10.1016\/j.ejpn.2023.05.001_bib6","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1212\/WNL.0000000000001045","article-title":"Onset of multiple sclerosis before adulthood leads to failure of age-expected brain growth","volume":"83","author":"Aubert-Broche","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.ejpn.2023.05.001_bib7","doi-asserted-by":"crossref","unstructured":"L.E. Charvet, E.H. O\u2019Donnell, A.L. Belman, T. Chitnis, J.M. Ness, J. Parrish, et al., Longitudinal evaluation of cognitive functioning in paediatric multiple sclerosis: report from the US Paediatric Multiple Sclerosis Network, Multi. Scleros. J.20(11):1502-10 (31 mars 2014).","DOI":"10.1177\/1352458514527862"},{"issue":"25","key":"10.1016\/j.ejpn.2023.05.001_bib8","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa067597","article-title":"Natural history of multiple sclerosis with childhood onset","volume":"356","author":"Renoux","year":"2007","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ejpn.2023.05.001_bib9","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1177\/1352458517732843","article-title":"Therapy of highly active pediatric multiple sclerosis","volume":"25","author":"Huppke","year":"2019","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.ejpn.2023.05.001_bib10","first-page":"58","article-title":"Consistent control of disease activity with fingolimod versus IFN \u03b2-1a in paediatric-onset multiple sclerosis: further insights from PARADIGMS","volume":"91","author":"Deiva","year":"2020","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"issue":"10","key":"10.1016\/j.ejpn.2023.05.001_bib11","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1177\/1352458513484547","article-title":"International Paediatric Multiple Sclerosis Study Group criteria for paediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions","volume":"19","author":"Krupp","year":"2013","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.ejpn.2023.05.001_bib12","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.ejpn.2023.05.001_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-4642(18)30026-9","article-title":"MRI and laboratory features and the performance of international criteria in the diagnosis of multiple sclerosis in children and adolescents: a prospective cohort study","volume":"2","author":"Fadda","year":"2018","journal-title":"Lancet Child Adolescent Health"},{"issue":"2","key":"10.1016\/j.ejpn.2023.05.001_bib14","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1212\/NXI.0000000000000528","article-title":"Real-world validation of the 2017 McDonald criteria for pediatric MS","volume":"6","author":"Wong","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"11","key":"10.1016\/j.ejpn.2023.05.001_bib15","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1177\/1352458519863781","article-title":"Improved performance of the 2017 McDonald criteria for diagnosis of multiple sclerosis in children in a real-life cohort","volume":"26","author":"Hacohen","year":"2020","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.ejpn.2023.05.001_bib16","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/10618600.1996.10474713","article-title":"R: a language for data analysis and graphics","volume":"5","author":"Ihaka","year":"1996","journal-title":"J.\u00a0Comput. Graph Stat."},{"issue":"22","key":"10.1016\/j.ejpn.2023.05.001_bib17","doi-asserted-by":"crossref","first-page":"e2538","DOI":"10.1212\/WNL.0000000000007572","article-title":"Clinical trials of disease-modifying agents in paediatric MS: opportunities, challenges, and recommendations from the IPMSSG","volume":"92","author":"Waubant","year":"2019","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.ejpn.2023.05.001_bib18","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1177\/1352458520930620","article-title":"The introduction of new medications in paediatric multiple sclerosis: open issues and challenges","volume":"27","author":"Ghezzi","year":"2021","journal-title":"Mult. Scler."},{"issue":"12","key":"10.1016\/j.ejpn.2023.05.001_bib19","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S1474-4422(21)00364-1","article-title":"Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial","volume":"20","author":"Chitnis","year":"2021","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.ejpn.2023.05.001_bib20","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ana.25737","article-title":"Real-world effectiveness of initial disease-modifying therapies in pediatric multiple sclerosis","volume":"88","author":"Krysko","year":"2020","journal-title":"Ann. Neurol."},{"issue":"4","key":"10.1016\/j.ejpn.2023.05.001_bib21","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001008","article-title":"Use of disease-modifying therapies in pediatric relapsing-remitting multiple sclerosis in the United Kingdom","volume":"8","author":"Abdel-Mannan","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"8","key":"10.1016\/j.ejpn.2023.05.001_bib22","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1177\/1352458512471878","article-title":"Natalizumab in paediatric multiple sclerosis: results of a cohort of 55 cases","volume":"19","author":"Ghezzi","year":"2013","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.ejpn.2023.05.001_bib23","first-page":"100","article-title":"No evidence of disease activity including cognition (NEDA-3 plus) in na\u00efve paediatric multiple sclerosis patients treated with natalizumab","volume":"267","author":"Margoni","year":"2020","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.ejpn.2023.05.001_bib24","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.pediatrneurol.2018.03.007","article-title":"Safety and efficacy of delayed-release dimethyl fumarate in paediatric patients with relapsing multiple sclerosis (FOCUS)","volume":"83","author":"Alroughani","year":"2018","journal-title":"Pediatr. Neurol."},{"issue":"6","key":"10.1016\/j.ejpn.2023.05.001_bib25","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1177\/1352458513507821","article-title":"Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial","volume":"20","author":"Vermersch","year":"2014","journal-title":"Mult. Scler."},{"issue":"19","key":"10.1016\/j.ejpn.2023.05.001_bib26","doi-asserted-by":"crossref","first-page":"e1778","DOI":"10.1212\/WNL.0000000000006471","article-title":"Use of newer disease-modifying therapies in paediatric multiple sclerosis in the US","volume":"91","author":"Krysko","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.ejpn.2023.05.001_bib27","article-title":"Clinical characteristics and use of disease modifying therapy in the nationwide Danish cohort of paediatric onset multiple sclerosis","volume":"37","author":"Erdal","year":"2020","journal-title":"Multi. Scleros. Relat. Disord."},{"issue":"4","key":"10.1016\/j.ejpn.2023.05.001_bib28","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s13311-017-0568-1","article-title":"Bringing the HEET: the argument for high-efficacy early treatment for paediatric-onset multiple sclerosis","volume":"14","author":"McGinley","year":"2017","journal-title":"Neurotherapeutics"},{"issue":"4","key":"10.1016\/j.ejpn.2023.05.001_bib29","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.msard.2015.04.006","article-title":"Is it time to target no evident disease activity (NEDA) in multiple sclerosis?","volume":"4","author":"Giovannoni","year":"2015","journal-title":"Multi. Scleros. Relat. Disord."},{"issue":"6","key":"10.1016\/j.ejpn.2023.05.001_bib30","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.msard.2014.09.088","article-title":"Treatment adherence and transitioning youth in paediatric multiple sclerosis","volume":"3","author":"Lulu","year":"2014","journal-title":"Mult Scler Relat. Disord."},{"issue":"2","key":"10.1016\/j.ejpn.2023.05.001_bib31","article-title":"Relapse rate and MRI activity in young adult patients with multiple sclerosis: a post hoc analysis of phase 3 fingolimod trials","volume":"4","author":"G\u00e4rtner","year":"2018","journal-title":"Multi.Scleros. J.- Experiment. Translat. Clin. avr"},{"issue":"8","key":"10.1016\/j.ejpn.2023.05.001_bib32","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1177\/1352458519846100","article-title":"Predictors of treatment outcome in patients with paediatric onset multiple sclerosis","volume":"26","author":"Kopp","year":"2020","journal-title":"Mult. Scler."}],"container-title":["European Journal of Paediatric Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379823000661?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379823000661?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T18:40:22Z","timestamp":1761072022000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1090379823000661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":32,"alternative-id":["S1090379823000661"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpn.2023.05.001","relation":{},"ISSN":["1090-3798"],"issn-type":[{"value":"1090-3798","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatments of paediatric multiple sclerosis: Efficacy and tolerance in a longitudinal follow-up study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Paediatric Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpn.2023.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}